Results 231 to 240 of about 40,034 (308)

Tubular Biomarkers and Retinal Microvasculature: Illuminating Early Cardiovascular-Kidney-Metabolic Pathways Beyond the Glomerulus. [PDF]

Kidney360
Cohen-Hagai K.
europepmc   +1 more source

Surface charge distribution is a determinant of antigen deposition in the renal glomerulus: studies employing ‘charge-hybrid’ molecules

, 1991
Stephen Batsford, M. J. Mihatsch, Marlies Rawiel, Thomas Schmiedeke, A Vogt   +4 more
openalex   +2 more sources

Model‐Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development (MIDD) played a crucial role in the successful development and regulatory approval of daprodustat, a novel oral hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHI) inhibitor aimed at treating anemia in chronic kidney disease patients.
Kelly M. Mahar, Shuying Yang, Brendan Johnson, Sandra A.G. Visser, Paul van den Berg, Martijn van Noort, Teun M. Post   +6 more
wiley   +1 more source

Adaptive filters at the first olfactory synapse. [PDF]

PLoS Biol
Moss EH, Arenkiel BR.
europepmc   +1 more source

Cystatin C‐based eGFR better predicts renal vancomycin clearance than creatinine‐based eGFR in patients with allogeneic stem cell transplantation

Clinical Pharmacology &Therapeutics, EarlyView.
Knowledge of the glomerular filtration rate (GFR) is mandatory when dosing renally eliminated drugs such as vancomycin. In clinical practice, different biomarkers and various equations are used to estimate GFR (eGFR), resulting in varying estimates.
Eva‐Maria A. Wansing, Sebastian G. Wicha, Peter Bannas, Alexander Heitkamp, Adrin Dadkhah, Nicolaus M. Kröger, Isabel Molwitz, Claudia Langebrake   +7 more
wiley   +1 more source

Beyond Heart Failure: A Case of Missed Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis. [PDF]

Cureus
Phyu EE, Yit C, San SS.
europepmc   +1 more source

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka, Michael Lawton, Tom Chu, Gary S. Friedman, Katrina Peron, Stefan R. Sultana, Warren E. Glaab, Nicholas M. P. King   +7 more
wiley   +1 more source

The effect of NF-kB and MAPK mediated Proinflammatory microenvironment on renal aging and amyloid deposition in elder rats. [PDF]

Sci Rep
Keçeci M, Özer CM, Babaoğlu E, Bodur F, Önal AC, Yılmazer Kayatekin AZ, Cengil O, Karataş AS.   +7 more
europepmc   +1 more source

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation

Clinical Pharmacology &Therapeutics, EarlyView.
From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park, Jae‐Hwan Lee, Jin‐Ok Jeong, Diana A. Gorog, Udaya S. Tantry, Byeong‐Keuk Kim, Hyung Joon Joo, Kiyuk Chang, Jin‐Yong Hwang, Young Bin Song, Sung Gyun Ahn, Jung‐Won Suh, Woong Gil Choi, Jung Rae Cho, Jeehoon Kang, Sang Yeub Lee, Hyo‐Soo Kim, Moo Hyun Kim, Do‐Sun Lim, Eun‐Seok Shin, Paul A. Gurbel, Young‐Hoon Jeong, on behalf of the PTRG‐DES Consortium Investigators   +22 more
wiley   +1 more source

Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5*6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
Pharmacogenomic research has historically focused on individuals of European ancestry, leading to the underrepresentation of genetic variants common in non‐European populations. This bias is exemplified by CYP3A5*6, a functionally consequential variant common in individuals of African ancestry (MAF: 11–19%) but virtually absent in Europeans (MAF: 0.15%)
Amar D. Levens, Dirk Jan A. R. Moes, Yanick Boer, Aiko P. J. de Vries, Dorottya K. de Vries, Danny van der Helm, Soufian Meziyerh, Dave L. Roelen, Stefan Böhringer, Teun Van Gelder, Jesse J. Swen   +10 more
wiley   +1 more source